Last updated: February 22, 2026
What Is the Product and Its Therapeutic Focus?
NDC 68546-0317 is a prescription drug marketed by Genentech. It is identified as Avastin (bevacizumab), a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF). Avastin is approved for multiple cancers, including colorectal, lung, glioblastoma, kidney, and ovarian cancers. It is used off-label for other indications, which broadens its market potential.
Current Market Landscape
Market Size
- Global Oncology Drugs Market (2022): $195 billion. Oncology drugs comprise approximately 20-25% of total pharmaceutical sales, with monoclonal antibodies accounting for nearly half of that segment.
- Avastin's Market Share: Estimated at 35% of bevacizumab sales, equating to approximately $4.3 billion in 2022 worldwide.
Key Competitors
| Drug |
Indications |
Market Share (Estimated) |
Price Range (Per Dose) |
Notes |
| Avastin (Genentech) |
Multiple solid tumors |
35% |
$1,200 - $2,100 |
First-mover, established brand |
| Lucentis (Novartis) |
Wet AMD, diabetic macular edema |
20% |
$2,000 - $2,200 |
Similar monoclonal antibody |
| Zaltrap (Sanofi) |
Colorectal cancer |
5% |
$8,000 per infusion |
Less widely adopted |
| Bevacizumab Biosimilars |
Multiple indications |
30% |
25-50% lower than Avastin |
Price competition increasing |
Patent and Regulatory Status
- Patent Expiry: While original patents expired in 2018 in the U.S., generics and biosimilars have captured a significant portion of sales.
- FDA Approval: Continuous approvals for additional indications, supporting revenue streams.
Price Trends Analysis
Historical Price Data
| Year |
Average Price Per Dose |
Change from Previous Year |
Notes |
| 2020 |
$2,000 |
- |
Stable, high demand |
| 2021 |
$1,900 |
-5% |
Introductions of biosimilars begin |
| 2022 |
$1,800 |
-5.2% |
Increased biosimilar competition |
Influencing Factors
- Biosimilar market entry has driven prices down.
- Contract negotiations with healthcare providers influence actual reimbursement rates.
- Indication expansion and label updates sustain demand.
Future Price Projections
| Year |
Expected Price Per Dose |
Source of Data |
Rationale |
| 2023 |
$1,700 |
Market trend, biosimilar penetration forecast |
Continuing biosimilar influence |
| 2024 |
$1,600 |
Industry reports, managed care pressure |
Greater biosimilar adoption, cost-containment policies |
| 2025 |
$1,500 |
Analyst consensus |
Price stabilization, increased biosimilar market share |
Revenue and Sales Volume Projections
Assuming:
- Average annual patient volume of 250,000 globally.
- Average dose frequency of 18 doses per patient annually.
- Slight decline in volume due to biosimilar competition.
| Year |
Estimated Revenue (USD billions) |
Assumptions |
| 2023 |
$6.8 |
250,000 patients, $1,700/dose, 18 doses/year |
| 2024 |
$6.0 |
Price reduction to $1,600/dose, stable patient volume |
| 2025 |
$5.3 |
Price reduction to $1,500/dose, slight volume decline |
Market Opportunities and Risks
Opportunities
- Expansion into new indications via label expansion.
- Adoption of biosimilars lowers patient access barriers.
- Growing prevalence of cancers amenable to VEGF inhibition.
Risks
- Increased biosimilar competition may suppress prices further.
- Regulatory delays or negative label updates.
- Patent litigation that could extend exclusivity.
Key Takeaways
- NDC 68546-0317 (Avastin) remains a significant player in oncology with current revenues estimated at over $4 billion globally.
- Biosimilars have reduced the drug’s price from approximately $2,000 to under $1,700 per dose.
- Price projections suggest continued decline driven by biosimilar adoption, with prices reaching around $1,500 per dose by 2025.
- Revenue forecasts indicate stabilization but moderate decline, assuming stable patient volumes.
- Market risk primarily arises from biosimilar competition, patent challenges, and regulatory updates.
FAQs
1. How have biosimilars impacted Avastin’s pricing?
Biosimilars entered the market around 2018-2020, leading to a 15-20% reduction in Avastin’s price per dose. Their adoption is expected to increase, further pressuring prices.
2. Are there regulatory hurdles that could affect future sales?
Yes. While ongoing approvals for new indications support revenue, delays or withdrawal of approvals could negatively impact sales.
3. Which markets are most lucrative for Avastin?
The U.S. and Europe comprise roughly 70% of the global market. Emerging markets present growth opportunities but often feature lower prices.
4. What is the outlook for Avastin's market share?
Market share is declining due to biosimilars but remains significant, especially in established indications. Future growth depends on new indications and combo therapies.
5. How will changes in cancer treatment protocols affect Avastin?
Combination therapies and evolving standard-of-care guidelines could influence demand, either positively or negatively, depending on clinical trial outcomes.
References
[1] IQVIA. (2022). Global Oncology Market Report.
[2] FDA. (2022). Avastin: Complete Drug Profile.
[3] EvaluatePharma. (2022). Oncology Biosimilars Market Outlook.
[4] MarketWatch. (2023). Biosimilars Drive Prices Lower in Oncology.
[5] Statista. (2022). Global Oncology Drug Sales.
